LASSA FEVER VACCINE STUDY
The Center for Vaccine Development and Global Health (CVD) is conducting a study to evaluate the effectiveness of a novel, first-in-human vaccine to protect against Lassa Fever.
The Lassa virus occurs in West Africa and impacts as many as 300,000 people a year. It is transmitted to humans mainly through food or household items contaminated by rats. While 80% of those infected with the virus will have no or mild symptoms, one in five people will develop a severe disease. Approximately one-third of infected individuals will develop hearing loss regardless of disease severity.
Prevention of illness through vaccination is a critical goal in reducing the burden of disease from Lassa Fever. There are currently no vaccines or therapeutics demonstrated to be efficacious in the prevention or treatment of Lassa Fever.
Qualified Participants Must:
Qualified Participants Will Receive:
Ready to get started?
Call: 410-706-8800 (8am-4pm)
Email: clintrial@som.umaryland.edu
Or complete our contact form.